Investment Thesis
AbbVie demonstrates strong operating profitability (26.6% operating margin, 80.4% gross margin) and solid free cash flow generation ($3.6B), but faces critical structural and growth challenges. Zero revenue growth, declining EPS, negative stockholders' equity of -$6.7B, and weak liquidity ratios (0.80 current) indicate a financially stressed company with limited strategic flexibility despite healthy core operations.
Strengths
- Excellent operating margin of 26.6% and gross margin of 80.4% demonstrate pricing power and operational efficiency
- Strong free cash flow generation of $3.6B with 23.8% FCF margin provides debt service capacity
- Adequate interest coverage of 5.6x provides cushion for debt obligations
- Operating cash flow of $3.8B confirms core business generates substantial cash despite balance sheet stress
Risks
- Negative stockholders' equity of -6.7B represents severe balance sheet distress limiting strategic options
- Zero revenue growth combined with 1% net income growth signals stagnation in mature pharmaceutical business
- Liquidity crisis indicators: current ratio 0.80x and quick ratio 0.68x both below safe thresholds
- Excessive debt burden of $64.5B creates refinancing risk and constrains capital allocation
- Diluted EPS declining 1.3% YoY despite negligible revenue growth indicates deteriorating shareholder economics
Key Metrics to Watch
- Revenue growth rate - must achieve positive growth to justify current operations
- Debt reduction progress and timeline to restore positive stockholders' equity
- Free cash flow sustainability and operating cash flow maintenance under liquidity pressure
- Current and quick ratios improvement toward 1.0x+ thresholds
- EPS trajectory reversal and organic revenue growth acceleration
Financial Metrics
Revenue
15.0B
Net Income
695.0M
EPS (Diluted)
$0.39
Free Cash Flow
3.6B
Total Assets
136.5B
Cash
9.4B
Profitability Ratios
Gross Margin
80.4%
Operating Margin
26.6%
Net Margin
4.6%
ROE
N/A
ROA
0.5%
FCF Margin
23.8%
Balance Sheet & Liquidity
Current Ratio
0.80x
Quick Ratio
0.68x
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
5.56x
Long-term Debt
64.5B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T07:23:11.012817 |
Data as of: 2026-03-31 |
Powered by Claude AI